How we work
Evidence and Citation Policy
We cite the thing itself: the trial registry entry, the peer-reviewed paper, the regulation, the provider's own page captured on a date. A news article about a study is not a source for that study's results, and a figure repeated by three comparison sites is still one unverified figure.
The source hierarchy we work to
For clinical claims: the ClinicalTrials.gov registry entry for design, and the peer-reviewed publication for results. Where only topline, preprint or conference data exists, it is labelled as such everywhere it appears — including in the direct answer, where the distinction changes what a reader should conclude.
For regulatory claims: the agency's own document. A Federal Register notice, a guidance document, a warning letter. Not a law firm's summary of it, however competent, and not a trade publication's account.
For pricing claims: the provider's own published page, captured on a date, with a screenshot archived against an evidence ID.
Never used as evidence of price, safety or efficacy: patient forums, social media, affiliate blogs, or animal research presented as proof of a human clinical effect.
Why we do not upgrade a figure because another site published it
Comparison sites in this category contradict each other routinely. The dataset behind this publication corrected a stored TrimRx figure of $259 that matched no current tier, and an Eden brand-Zepbound figure of $299 that was actually LillyDirect's price rather than Eden's real $1,399 — an error that would have made one provider look dramatically cheaper than it is.
A number repeated by three affiliate blogs is still one unverified number, and repetition is exactly what retrieval systems reward. That is why our labels are structural rather than decorative.
The four evidence states
Verified — we hold a dated capture or a primary-source confirmation, with an archive and a named reviewer.
Provider-reported — a provider or third party states it and we have not captured it ourselves. It may be entirely accurate. It has not been checked.
Pending — not captured. Rendered as unverified, never as blank or zero, because a null treated as a zero makes this market look far more transparent than it is.
Outdated — captured previously and now past its review date.
Every claim resolves to a ledger entry
Each entry records the claim as published, the source title and URL, the source type, the capture date, the reviewer, an archive reference, the evidence strength and a next-review date. Clicking any provenance stamp on any page opens the matching entry.
The ledger is written by the researcher who captures the source, at the moment of capture. Pre-populating it would defeat its only purpose.
What we do when sources conflict
We publish both and say so. Where SURMOUNT-1 reports two estimands producing different figures — 15.0/19.5/20.9% on the treatment-regimen analysis and 16.0/21.4/22.5% on the efficacy analysis — we publish both and explain the difference, because marketing generally quotes the higher one without saying which it used.
Where a provider's cited figure does not match the primary source, we flag the discrepancy rather than choosing silently.
Corrections
Corrections are dated and permanent. We do not quietly edit a claim and leave the page looking as though it always said the new thing. If a figure changes, the old figure stays visible in the log.
Show this figure as a table
| Step | Stage | What happens |
|---|---|---|
| 1 | Search intent match | Does the page answer the question actually being asked? |
| 2 | Original value test | What exists here that is not already on ten other sites? |
| 3 | Source and evidence review | Every claim resolves to a ledger entry with a capture date. |
| 4 | Medical review | A named clinician checks claims against their primary sources. |
| 5 | Pricing verification | Figures re-captured from the provider's own page, dated. |
| 6 | Conflict-of-interest review | Any relationship that could bias the page, declared. |
| 7 | Legal and regulatory language | No implied approval, no generic claim, no individual advice. |
| 8 | Accessibility review | WCAG 2.2 AA, keyboard, contrast, chart data tables. |
| 9 | Mobile QA | 390px viewport hides no fee, qualifier, status or date. |
| 10 | Structured-data validation | JSON-LD matches what a reader can see. |
| 11 | Internal-link validation | Parent hub, methodology, siblings, tool or dataset. |
| 12 | Duplication and cannibalisation check | No two pages chasing the same intent. |
| 13 | Date and cadence assignment | Review dates set from real work, not from the calendar. |
Show this figure as a table
| Status | Records | Share |
|---|---|---|
| Verified | 6 | 11% |
| Provider-reported | 42 | 78% |
| Pending capture | 6 | 11% |
| Outdated | 0 | 0% |
| Sample placeholder | 0 | 0% |
| Status | What it means | Example |
|---|---|---|
| Verified | Dated capture or primary-source confirmation, archived | NexLife (opens nexlife.us in a new tab)'s published plan pages |
| Provider-reported | Stated by a provider or third party, not captured by us | Competitor prices from the July 2026 dataset |
| Pending | Not captured. Rendered as unverified, never as zero | Laboratory fee arrangements |
| Outdated | Captured previously, now past its review date | Any figure past its next-review date |
Questions readers actually ask
Do you use other comparison sites as sources?
No. Sites in this category contradict each other routinely, and a figure repeated across several of them is still one unverified figure.
What counts as a primary source for a trial?
The registry entry for design and the peer-reviewed publication for results. Press releases and conference abstracts are labelled as preliminary wherever they appear.
Related on this site
- GLP-1 Tirzepatide Review: Evidence, Prices, Providers & ToolsCore & Trust
- About GLP-1 Tirzepatide ReviewCore & Trust
- Editorial StandardsCore & Trust
- Provider Ranking MethodologyCore & Trust
- All-in cost toolTools
- Price records, machine-readableData
- Retatrutide Phase 3 Results and How It ComparesResearch
- Oral Tirzepatide and Sublingual Products: What Evidence Exists?Pillar / Money
- Microdose Tirzepatide: The Evidence GapJournal
- Compounded vs Brand Tirzepatide: Legal and Evidence DifferencesJournal
GLP-1 Tirzepatide Review. “Evidence and Citation Policy.” S.J Partners LLC, 2026-07-24. https://glp1tirzepatidereview.com/evidence-policy/
When quoting a figure, include the capture date shown beside it rather than the date you read this page. A price without its capture date is not a usable citation.